Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Baricitinib Plus Danazol in Steroid-resistant/Relapse ITP
NCT05852847Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
baricitinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05852847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852847.